Stephanie Read is the Chief Executive Officer of Highland Therapeutics.
In addition to serving as the newly appointed CEO of Ironshore, Stephanie will continue to have a seat on the Highland-Ironshore Board. Ms. Read also serves as a Non-Executive Director on the Board of ALSP Orchid Acquisition Corporation I (NASDAQ:ALORU). Ms. Read's 24-year biopharmaceutical career spans Global Research and Development, Medical Affairs, Alliance Management, Commercial and Business Development and Equity Investing. All leadership roles have included driving transformational change within organizations to accelerate top and bottom line growth, and diversification of company portfolios. Ms. Read's therapy area expertise includes Psychiatry (inventorship of MYDAYIS), Gastroenterology, Oncology & Pain, Infectious Disease, Immunology and Rare Diseases. Ms. Read's industry appointments include the last 6.5 years with CSL (CSL:ASX) as global VP, Corporate Strategy and Business Development, 7.5 years with AstraZeneca/MedImmune (AZN) in a variety of Medical Affairs, Commercial and Business Development roles, and over 6 years with Shire PLC in R&D and Global Medical Affairs (including inventing, developing and launching new treatments for ADHD).
Stephanie holds a M.Sc. in Biotechnology from The Johns Hopkins University and a B.Sc. in Biology from Virginia Tech.